Literature DB >> 31509363

Melatonin suppression by melanopsin-weighted light in patients with bipolar I disorder compared to healthy controls

Philipp Ritter1, Falk Wieland1, Debra J. Skene1, Andrea Pfennig1, Maria Weiss1, Michael Bauer1, Emanuel Severus1, Henry Güldner1, Cathrin Sauer1, Bettina Soltmann1, Stefanie Neumann1.   

Abstract

Background: Multiple lines of evidence suggest that the onset and course of bipolar disorder is influenced by environmental light conditions. Increased suppression of melatonin by light (supersensitivity) in patients with bipolar disorder has been postulated as an endophenotype by several studies. However, due to methodological shortcomings, the results of these studies remain inconclusive. This study investigated melatonin suppression in euthymic patients with bipolar I disorder using evening blue light specifically targeting the melanopsin system.
Methods: Melatonin suppression was assessed in euthymic patients with bipolar I disorder and healthy controls by exposure to monochromatic blue light (λmax = 475 nm; photon density = 1.6 × 1013 photons/cm2/s) for 30 minutes at 2300 h, administered via a ganzfeld dome for highly uniform light exposure. Serum melatonin concentrations were determined from serial blood sampling via radioimmunoassay. All participants received mydriatic eye drops and were genotyped for the PER3 VNTR polymorphism to avoid or adjust for potential confounding. As secondary outcomes, serum melatonin concentrations during dark conditions and after monochromatic red light exposure (λmax = 624 nm; photon density = 1.6 × 1013 photons/cm2/s) were also investigated. Changes in subjective alertness were investigated for all 3 lighting conditions.
Results: A total of 90 participants (57 controls, 33 bipolar I disorder) completed the study. Melatonin suppression by monochromatic blue light did not differ between groups (F1,80 = 0.56; p = 0.46). Moreover, there were no differences in melatonin suppression by monochromatic red light (F1,82 = 1.80; p = 0.18) or differences in melatonin concentrations during dark conditions (F1,74 = 1.16; p = 0.29). Healthy controls displayed a stronger increase in subjective alertness during exposure to blue light than patients with bipolar I disorder (t85 = 2.28; p = 0.027). Limitations: Large interindividual differences in melatonin kinetics may have masked a true difference.
Conclusion: Despite using a large cohort and highly controlled laboratory conditions, we found no differences in melatonin suppression between euthymic patients with bipolar I disorder and healthy controls. These findings do not support the notion that supersensitivity is a valid endophenotype in bipolar I disorder.
© 2019 Joule Inc. or its licensors

Entities:  

Year:  2019        PMID: 31509363     DOI: 10.1503/jpn.190005

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  3 in total

1.  Melanopsin-mediated pupillary responses in bipolar disorder-a cross-sectional pupillometric investigation.

Authors:  Helle Østergaard Madsen; Shakoor Ba-Ali; Steffen Heegaard; Ida Hageman; Ulla Knorr; Henrik Lund-Andersen; Klaus Martiny; Lars Vedel Kessing
Journal:  Int J Bipolar Disord       Date:  2021-03-01

Review 2.  Adjunctive bright light therapy for treating bipolar depression: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Hirofumi Hirakawa; Takeshi Terao; Masaaki Muronaga; Nobuyoshi Ishii
Journal:  Brain Behav       Date:  2020-10-09       Impact factor: 2.708

Review 3.  Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar disorder: A critical multi-disciplinary literature review and agenda for future research from the ISBD task force on chronobiology.

Authors:  Michael J McCarthy; John F Gottlieb; Robert Gonzalez; Colleen A McClung; Lauren B Alloy; Sean Cain; Davide Dulcis; Bruno Etain; Benicio N Frey; Corrado Garbazza; Kyle D Ketchesin; Dominic Landgraf; Heon-Jeong Lee; Cynthia Marie-Claire; Robin Nusslock; Alessandra Porcu; Richard Porter; Philipp Ritter; Jan Scott; Daniel Smith; Holly A Swartz; Greg Murray
Journal:  Bipolar Disord       Date:  2021-12-10       Impact factor: 5.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.